Ralliant Corporation (NYSE:RAL) to Issue Quarterly Dividend of $0.05

by · The Markets Daily

Ralliant Corporation (NYSE:RAL – Get Free Report) announced a quarterly dividend on Tuesday, August 4th. Investors of record on Tuesday, September 8th will be paid a dividend of 0.05 per share on Wednesday, September 23rd. This represents a c) dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 8th.

Ralliant Stock Performance

NYSE RAL opened at $67.13 on Wednesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41. The company has a market capitalization of $7.43 billion, a PE ratio of -6.19, a P/E/G ratio of 2.42 and a beta of 1.60. The company has a fifty day moving average of $67.37 and a two-hundred day moving average of $54.54.

Ralliant (NYSE:RAL – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The business had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, analysts expect that Ralliant will post 2.87 earnings per share for the current year.

Ralliant Company Profile

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Recommended Stories